Assay News and Research

RSS

A potential therapeutic target for gastric cancer

Gastric cancer (GC) is the fourth most common malignancy and the second most frequent cause of cancer-related death in the world.

20 Apr 2009

Tijuana injection drug users on collision course for HIV and tuberculosis

A study by researchers from the University of California, San Diego School of Medicine, in collaboration with Mexican researchers and health officials, shows that as many as 67 percent of injection drug users in Tijuana test positive for tuberculosis (TB) infection.

15 Apr 2009

African sleeping sickness parasite breaks its own DNA to avoid detection

The parasite Trypanosoma brucei, which causes African sleeping sickness, is like a thief donning a disguise.

15 Apr 2009

$Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma$

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009

Axela launches nine plate based tumor marker assays

Available in high performance ELISA format they have been designed for stand alone use or to simplify the transition to automated dotLab assays.

9 Apr 2009

Fluorescent anesthetic compound brings new avenues for drug discovery

A collaboration of University of Pennsylvania and University of Wisconsin chemists and anesthesiologists have identified a fluorescent anesthetic compound that will assist researchers in obtaining more precise information about how anesthetics work in the body and will provide a means to more rapidly test new anesthetic compounds in the search for safer and more effective drugs.

6 Apr 2009

FDA looks at nanotechnology for the detection of anthrax

The U.S. Food and Drug Administration has completed a "proof-of-concept" study of a test that quickly and accurately detects the presence of even the smallest amount of the deadly anthrax toxin.

17 Mar 2009

Sensitive new test for protein detection

Scientists at the Naval Research Laboratory (NRL) recently reported the detection of toxins with unprecedented speed, sensitivity, and simplicity.

16 Mar 2009

Phylonix granted broad U.S. patent for assessing cardiac functions in Zebrafish

Phylonix Pharmaceuticals announced, at the Society of Toxicology Annual Meeting in Baltimore, that the U.S. Patent and Trademark Office has issued the company a broad patent for assessing the toxicity of pharmaceutical test agents on cardiovascular functions in zebrafish.

15 Mar 2009

Axela introduces dotLab Amine Reactive Sensor

Axela Inc has introduced the dotLab Amine Reactive Sensor for stable covalent coupling of affinity reagents such as antibodies for use with the Axela dotLab System.

4 Mar 2009

Protein function and chromatin structure methods featured in Cold Spring Harbor Protocols

Two new methods for analyzing the roles played by proteins in cells are featured in the March issue of Cold Spring Harbor Protocols.

3 Mar 2009

Scientists develop general-purpose method for detecting trace chemicals

Described in an advance, online publication of the journal Nature Biotechnology on February 22, 2009, the team's general method could be adapted for detecting a wide variety of compounds, including many that are relevant to diagnostic medicine and environmental work.

26 Feb 2009

New technique to determine tumor methylation status

Current research suggests that a new technique to determine tumor methylation status can be used in archived tissue samples.

23 Feb 2009

Idenix Pharmaceuticals and GSK sign agreement for novel NNRTI for treatment of HIV

Idenix Pharmaceuticals, Inc. and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.

8 Feb 2009

NRL partners with industry to develop compact biosensor for wide-ranging applications

Scientists at the Naval Research Laboratory (NRL) are partnering with industry to develop a sensor system for biomolecules that could make a significant contribution to a variety of fields such as healthcare, veterinary diagnostics, food safety, environmental testing, and national security.

3 Feb 2009

Robot scientist promises to dig up new drugs

A robot scientist that can make informed guesses about how effective different chemical compounds will be at fighting different diseases could revolutionise the pharmaceutical industry by developing more effective treatments more cheaply and quickly than current methods.

3 Feb 2009

SAFC Pharma augments assay development capabilities

SAFC Pharma, a business segment of SAFC, a member of the Sigma-Aldrich group, today announced that it has commenced operations at its 7,000 sq. ft. state-of-the-art laboratory complex in Carlsbad, CA.

29 Jan 2009

Biodegradable nanoprobe images new blood vessel growth

Angiogenesis, the growth of new blood vessels, plays a critical role in several chronic human diseases, including metastatic cancer. In fact, several new anticancer therapies are designed to starve tumors by shutting down angiogenesis, but the lack of a good assay for quantifying angiogenesis in the body has hampered the development of effective antiangiogenesis therapies.

18 Jan 2009

New methods for studying DNA repair and protein modification

This month's issue of Cold Spring Harbor Protocols features two articles detailing experimental methods for the analysis of molecular processes involved in DNA repair and post-translational modification of proteins.

5 Jan 2009

Why prostate cancer patients fail hormone deprivation therapy

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.

1 Jan 2009